{"id":"NCT00920816","sponsor":"Pfizer","briefTitle":"Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer","officialTitle":"AG-013736 (AXITINIB) FOR THE TREATMENT OF METASTATIC RENAL CELL CANCER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08-25","primaryCompletion":"2012-07-27","completion":"2021-04-29","firstPosted":"2009-06-15","resultsPosted":"2014-02-04","lastUpdate":"2022-05-06"},"enrollment":492,"design":{"allocation":"RANDOMIZED","model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Kidney Neoplasms"],"interventions":[{"type":"DRUG","name":"Axitinib (AG-013736)","otherNames":[]},{"type":"DRUG","name":"Sorafenib","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"ACTIVE_COMPARATOR"}],"summary":"The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.","primaryOutcome":{"measure":"Progression Free Survival (PFS): First-Line Participants","timeFrame":"Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)","effectByArm":[{"arm":"Axitinib (First-line Participants)","deltaMin":10.1,"sd":null},{"arm":"Sorafenib (First-line Participants)","deltaMin":6.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":125,"countries":["United States","Bosnia and Herzegovina","Bulgaria","Chile","China","India","Malaysia","Mexico","Philippines","Romania","Russia","South Africa","Taiwan","Ukraine"]},"refs":{"pmids":["37526095","37146227","33947608","28410911","27498023","27238653","26089686","24206640"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061051&StudyName=Axitinib%20%28AG-013736%29%20For%20the%20Treatment%20of%20Metastatic%20Renal%20Cell%20Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":173},"commonTop":["Diarrhoea","Hypertension","Weight decreased","Fatigue","Palmar-plantar erythrodysaesthesia syndrome"]}}